Navigation Links
Isis Earns $5 Million in Milestone Payment from GSK for Advancement of ISIS-GSK4 Rx
Date:11/15/2013

CARLSBAD, Calif., Nov. 15, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $5 million milestone payment from GlaxoSmithKline (NYSE: GSK) related to the designation of ISIS-GSK4Rx as a development candidate.  ISIS-GSK4Rx is an antisense drug designed to treat an undisclosed ocular disease. 

(Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO)

"Our collaboration with GlaxoSmithKline has been very productive resulting in three novel antisense drugs in our pipeline," said B. Lynne Parshall, chief operating officer at Isis.  "We look forward to advancing ISIS-GSK4Rx into the clinic and providing more information on the target and disease opportunity, which we are very excited about." 

As a part of the alliance, Isis is eligible to earn additional pre-licensing milestone payments from GlaxoSmithKline as ISIS-GSK4Rx advances.  Isis will develop ISIS-GSK4Rx to Phase 2 proof-of-concept, at which time GlaxoSmithKline has an option to exclusively license it.   Isis is also eligible to receive double-digit royalties on sales of ISIS-GSK4Rx

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 31 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Isis' strategic alliance with GlaxoSmithKline and the discovery, development and therapeutic potential of ISIS-GSK4Rx for the treatment of an undisclosed ocular disease.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.



'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Isis Pharmaceuticals Earns $1.5M from the Advancement of the Phase 2 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
2. NEBA Health earns patent for integration of NEBA biomarker with clinicians ADHD evaluation
3. Isis Pharmaceuticals Earns $2 Million from GSK for the Advancement of ISIS-TTR Rx
4. Elektas Leksell Gamma Knife Perfexion Earns Top Rank in 2013s Best in KLAS for Radiation Therapy
5. Isis Pharmaceuticals Earns $6 Million Payment from AstraZeneca
6. Isis Pharmaceuticals Earns $3.5 Million from Biogen Idec
7. GlySure Earns ISO 13485 Certification
8. Isis Initates Phase 2/3 Study Of ISIS-TTR Rx And Earns $7.5 Million Milestone Payment From GlaxoSmithKline
9. MedicareBlue Rx Drug Plan Earns Federal Governments Top Rating
10. Agendia Earns ISO Certification for Facilities in Amsterdam and Irvine
11. Cardiac Science Earns Top Marks for Cardiac Stress Test, Telemetry Monitor Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... -- TARE (Transarterial Radio-embolization) Using Yttrium-90 ... Overall Decreased Use of Hospital Resource ... healthcare company, has today announced the publication of ... ISPOR (International Society for Pharmacoeconomics and Outcomes Research), ... yttrium-90 glass microspheres is associated with cost savings ...
(Date:5/25/2016)... According to a new market ... 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application ... Manufacturers, Hospitals/ Clinics) - Forecast to 2021", published by ... for the forecast period of 2016 to 2021. This ... 2021 from USD 117.3 Million in 2016, at a ...
(Date:5/25/2016)... NEW YORK , May 25, 2016  According ... devices reached $381 billion in 2015.  Though these ... still plenty of opportunity for success for companies ... end, in search of new growth prospects medical ... revenue on research and development (R&D) than do ...
Breaking Medicine Technology:
(Date:5/28/2016)... California (PRWEB) , ... May 28, 2016 , ... "Color ... to drag and drop a preset onto their media," said Christina Austin - CEO ... Film Studios, editors can quickly and easily add stylish color grades to their footage. ...
(Date:5/28/2016)... ... May 28, 2016 , ... After a year and a half of planning the ... event. The Multiple Pathways of Recovery Conference was held May 2 -4, 2016 at ... the United Kingdom came together to explore the many pathways individuals use to get into ...
(Date:5/27/2016)... Angeles, CA (PRWEB) , ... May 27, 2016 , ... ... of Health, so it is not surprising that bariatric surgery has received increased attention ... Business Journal explains. Of course, when it comes to weight loss, most people are ...
(Date:5/27/2016)... ... , ... Two director-level employees of Horizon Blue Cross Blue Shield of New ... honorees. The award recognizes businesswomen who excel in their fields and who have ... MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health and Theresa Ponton, ...
(Date:5/27/2016)... ... ... An influential resource amongst nurses and professionals in the health care world, ... of topics detailing why we appreciate nurses in so many different ways. From exclusive ... being in a major recession to one of the hottest growing professions in any ...
Breaking Medicine News(10 mins):